sequencing-based diagnostics
Clarified Precision Medicine Acquires Molecular Diagnostics Firm Interpares Biomedicine
The acquisition brings Interpares' genetic sequencing test, OncoGuardian, into Clarified's portfolio of precision medicine products.
Congenica, Gabriel Precision Oncology Partner on Clinical Interpretation for Somatic Cancer Testing
University of Glasgow spinout Gabriel Precision Oncology will contribute a bioinformatics pipeline derived from cancer tissue samples to accelerate MDx adoption.
Illumina CEO Discusses Pan-Cancer IVD Assay, CDx Collaborations at JP Morgan
The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.
Adaptive Biotechnologies, GlaxoSmithKline Collaborate on MRD Testing
In a non-exclusive deal, GlaxoSmithKline will use Adaptive Biotechnology's NGS-based ClonoSeq test to assess MRD across its hematology portfolio.
Adaptive Biotechnologies Receives Expanded FDA Clearance for ClonoSeq MRD Assay
The sequencing-based test for minimal residual disease can be use with blood and bone marrow samples in patients with chronic lymphocytic leukemia.